Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is a clinical-stage biopharmaceutical company developing selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company's lead candidate, vidofludimus calcium, has a novel dual-mechanism with both neuroprotective and anti-inflammatory effects, making it a promising treatment for relapsing multiple sclerosis (RMS) patients. With the Phase 3 clinical trial expected to report topline data by the end of 2026 and plans for a confirmatory Phase 3 program for primary progressive MS, Immunic has strong potential for future growth. However, the recent reverse stock split and dilution risks may outweigh the near-term clinical upside. Investors should also consider potential risks such as clinical/regulatory, financial, and market share risks before investing in this company.

Bears say

Immunic is facing multiple challenges in the near term, including potential technical pressure surrounding reverse split, follow-on financing activity, and changes in shareholder base that may impede its progress. Additionally, the company's late-stage program and capital-intensive nature may lead to a sub-optimal financial situation, despite its recent financing efforts. Finally, Immunic must prove the effectiveness and commercial viability of its lead asset in a competitive market, which may be hindered by its limited cash reserves and shareholder overhang.

Immunic Inc (IMUX) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.